Influence of ibandronic acid therapy on outcomes of medical rehabilitation of patients with postmenopausal osteoporosis: data from a 6-month follow-up

Introduction. Ibandronic acid is an important drug for osteoporosis therapy, with a pronounced antiresorptive effect. Despite its proven efficacy, questions remain regarding its role in maintaining long-term effects after medical rehabilitation.
Aim. Assess the effect of the drug Rezoviva 150 mg (oral ibandronic acid) treatment on the duration of maintenance of the medical rehabilitation effect in postmenopausal women with diagnosed osteoporosis undergoing the second stage of medical rehabilitation.
Materials and methods. The study included 70 women aged 45 and older, postmenopausal for more than one year, admitted for the second stage of medical rehabilitation due to musculoskeletal diseases with a diagnosis of postmenopausal osteoporosis. The women were randomized into two groups: the main group (n = 35), receiving Rezoviva (ibandronic acid, 150 mg tablets once monthly), and a comparison group (n = 35). All patients in both groups received cholecalciferol (vitamin D3) at an average dose of 1500 IU per day. Effectiveness was assessed after 6 months using a battery of functional tests for evaluating mobility, back and abdominal muscle strength, static and dynamic balance, as well as pain assessment using a 5-point VAS and quality
of life via the SF-36 questionnaire.
Results. After 6 months, the main group showed improved static (p = 0.017) and dynamic endurance of back muscles (p = 0.024 vs with the initial level; p = 0.030 vs with the comparison group), increased walking speed in the 10-meter walk test (p = 0.043), and decreased time to complete the “Get Up and Go” test (p = 0.035 vs baseline; p = 0.028 vs comparison group), compared to baseline and the comparison group. There was also a reduction in forward body sway in the Fukuda test (p = 0.035 vs baseline; p = 0.047 vs comparison group) and increased balance time on one leg with eyes open. Quality of life scores improved significantly in physical functioning, pain severity, and vitality domains in the main group. Pain reduction was only observed in the main group.
Conclusion. Preliminary data indicate that treatment with Rezoviva 150 mg (oral ibandronic acid) effectively maintains the benefits of medical rehabilitation in postmenopausal women with osteoporosis.

1. Belaya ZhE, Rozhinskaya LY, Grebennikova TA, Kanis JA, Pigarova EA, Rodionova SS et al. Summary of the draft federal clinical guidelines for osteoporosis. Osteoporosis and Bone Diseases. 2020;23(2):4–21. (In Russ.) https://doi.org/10.14341/osteo12710.

2. Curtis EM, Moon RJ, Harvey NC, Cooper C. The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Bone. 2017;104:29–38. https://doi.org/10.1016/j.bone.2017.01.024.

3. Men′shikova LV, Khramtsova NA, Yershova OB, Lesnyak OM, Kuz′mina LI, Anikin SG et al. Short- and long-term outcomes of proximal femur fractures in the elderly and their medical-social consequences: results of a multicenter study. Osteoporosis and Bone Diseases. 2002;(1):8–11. (In Russ.) Available at: https://cyberleninka.ru/article/n/blizhayshie-iotdalennye-ishody-perelomov-proksimalnogo-otdela-bedra-u-litspozhilogo-vozrasta-i-ih-mediko-sotsialnye-posledstviya-po.

4. Marchenkova LA, Makarova EV, Gerasimenko MYu, Vasileva VA, Yeremushkin MA, Styazhkina EM, Evstigneeva IS. The effectiveness of a new physical rehabilitation complex including mechanotherapy technologies in improving quality of life indicators in patients with osteoporotic vertebral compression fractures. Russian Journal of Physiotherapy, Balneology and Rehabilitation. 2020;19(1):51–58. (In Russ.) https://doi.org/10.17816/1681-3456-2020-19-1-8.

5. Jacobs E, McCrum C, Senden R, van Rhijn LW, Meijer K, Willems PC. Gait in patients with symptomatic osteoporotic vertebral compression fractures over 6 months of recovery. Aging Clin Exp Res. 2020;32(2):239–246. https://doi.org/10.1007/s40520-019-01203-9.

6. Gunay Ucurum S,Altas EU, Ozer Kaya D. Comparison of the spinal characteristics, postural stability and quality of life in women with and without osteoporosis. J Orthop Sci. 2020;25(6):960–965. https://doi.org/10.1016/j.jos.2019.12.015.

7. Marchenkova LA, Makarova EV, Gerasimenko MY, Evstigneeva IS. Assessment of osteoporotic fracture risk and prevalence of osteoporosis in patients aged 50 years and older undergoing medical rehabilitation. Russian Journal of Physiotherapy, Balneology and Rehabilitation. 2020;19(1):13–19. (In Russ.) https://doi.org/10.17816/1681-3456-2020-19-1-2.

8. Shibasaki K,Asahi T, Kuribayashi M, Tajima Y, Marubayashi M, Iwama R et al. Potential prescribing omissions of anti-osteoporosis drugs is associated with rehabilitation outcomes after fragility fracture: Retrospective cohort study. Geriatr Gerontol Int. 2021;21(5):386–391. https://doi.org/10.1111/ggi.14145.

9. Marchenkova LA, Makarova EV, Vasileva VA, Eryomushkin MA, Styazkina EM, Razvalyaeva DV et al. The effect of basic therapy with calcium and vitamins D3 and B6 on muscle strength, movement and balance functions at patients with osteoporosis undergoing medical rehabilitation. Problems of Balneology, Physiotherapy and Therapeutic Physical Culture. 2020;97(1):25–34. (In Russ.) https://doi.org/10.17116/kurort2020970112.

10. Marchenkova LA, Makarova EV, Vasileva VA. The influence of HDBA organic complex with vitamin D and calcium on quality of life in individuals at high risk of fractures undergoing medical rehabilitation. Vestnik Vosstanovitelʹnoj Mediciny. 2020;97(3):153–159. (In Russ.) https://doi.org/10.38025/2078-1962-2020-97-3-153-159.

11. Marchenkova LA, Fesyun AD, Gerasimenko MYu, Makarova EV. The effect of administration of a dietary supplement with calcium and vitamins D3 and B6 on calcium homeostasis and falls incidence in patients with high fracture risk undergoing medical rehabilitation. Voprosy Pitaniia. 2020;89(5):89–100. (In Russ.) https://doi.org/10.24411/0042-8833-2020-10069.

12. Еремушкин МА. Двигательная активность и здоровье. От лечебной гимнастики до паркура. М.: Спорт; 2016. 240 с.

13. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119(2):150–162. https://doi.org/10.1542/peds.2006-2023H.

14. Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more important than frequency of dosing of antiosteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int. 2011;22(3):741–753. https://doi.org/10.1007/s00198-010-1335-x.

15. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023–1031. https://doi.org/10.1007/s00198-006-0322-8.

16. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21(9):1453–1460. https://doi.org/10.1185/030079905X61875.

17. Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–1249. https://doi.org/10.1359/JBMR.040325.

18. Simonelli C, Burke MS. Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate. Curr Med Res Opin. 2006;22(6):1101–1108. https://doi.org/10.1185/030079906X104867.

19. Bauss F, Schimmer RC. Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Ther Clin Risk Manag. 2006;2(1):3–18. Available at: https://pubmed.ncbi.nlm.nih.gov/18360577.

20. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20(8):1315–1322. https://doi.org/10.1359/JBMR.050313.

21. Miller PD, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin. 2008;24(1):207–213. https://doi.org/10.1185/030079908x253889.

22. Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone. 2009;44(5):758–765. https://doi.org/10.1016/j.bone.2009.01.002.

23. Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P et al. The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30(5):934–944. https://doi.org/10.1002/jbmr.2442.

24. Reid IR, Horne AM, Mihov B, Phty B, Stewart A, Garratt E et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018;379(25):2407–2416. https://doi.org/10.1056/NEJMoa1808082.

25. Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporos Int. 2012;23(6):1769–1778. https://doi.org/10.1007/s00198-011-1793-9.